Wednesday, January 23, 2019

Lilly Announces Agreement To Acquire ARMO BioSciences

.6 billion transaction will bolster Lilly's clinical portfolio with ARMO's lead immuno-oncology asset, pegilodecakin, which is being studied in multiple tumor types Eli Lilly and Company and ARMO BioSciences, Inc. today announced a definitive agreement...

Autologous Stem Cell Therapy May Hold Key to Regeneration

USRM Chief Science Officer's Live Webinar Adds Voice to Debate U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the...

GCE Launches Groundbreaking New Product: Shadow

GCE Solutions, a global clinical research organization (CRO), announces the launch of Shadow, a powerful new data and document anonymization solution on October 4, 2017. Shadow is designed to assist medical writers and biometrics...

ADM Tronics Prepares New Respiratory Therapy Device for Market

ADM Tronics Unlimited, Inc. (OTCQB - ADMT) is in the final stage of developing the Alvio™ device, a new technology it has had under development pursuant to its previously announced agreement with QOL...

MiMedx Receives Regulatory Approval to Commercialize Product Portfolio in Australia

Partners with Leading Australian Healthcare Products and Biological Supplier MiMedx Group, Inc., a leading developer and marketer of regenerative and therapeutic biologics, today announced that it received regulatory approval from the Therapeutics Goods Administration (TGA)...

Virtual Reality in Medicine and Healthcare to Generate US$285 million in 2022

Therapy and Training Services have the highest opportunity in VR medical and healthcare segment Virtual Reality (VR) has brought a range of new services into the healthcare industry.  The immersive experience provided by VR...

The Menarini Group Announced Marketing Authorization Application for Delafloxacin

The Menarini Group announced today that on March 6th 2017 it submitted a Marketing Authorization Application for delafloxacin at the European Medicines Agency (EMA) under the trade name Quofenix. The proposed indication for delafloxacin in Europe is the...

Enhanced Healthcare Partners Announces Investment in SCA Pharmaceuticals

Enhanced Healthcare Partners ("EHP"), a private equity firm focused exclusively on investing in the healthcare industry, has announced its investment in SCA Pharmaceuticals ("SCA"), a sterile compounding leader specializing in preparing sterile pharmaceuticals...

Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study

The first drug designed to eliminate autoantibodies that are a major cause of heart failure and to treat heart failure symptoms was effective and well-tolerated in a Phase 1 clinical study, according to...

Aralez Pharmaceuticals To Enter Into Purchase Agreements To Sell Substantially All Assets

Company to Continue Operating Business and Serving Customers As Usual Aralez Pharmaceuticals Inc. announced today that it intends to enter into purchase agreements with two separate stalking-horse purchasers to sell its main operating businesses:  an...

Connect with us

4,525FansLike
1,007FollowersFollow
12,053FollowersFollow

Popular Posts